<DOC>
	<DOCNO>NCT00809718</DOCNO>
	<brief_summary>The aim study study effect rifapentine plasma concentration raltegravir .</brief_summary>
	<brief_title>The Effect Rifapentine Raltegravir</brief_title>
	<detailed_description>Primary Objective To compare pharmacokinetics parameter value ( geometric mean Cmin AUC ) raltegravir 400 mg q12h alone raltegravir 400 mg q12h co-administered combination rifapentine 900 mg weekly , raltegravir 400 mg q12h co-administered combination rifapentine 600 mg per day , 5 day per week . Secondary Objective To assess tolerability safety concomitant administration raltegravir rifapentine healthy volunteer . Design This study three-period , one-sequence , open label , pharmacokinetic study raltegravir-rifapentine interaction healthy , male female volunteer . Up 21 subject may enrol achieve estimate sample size 16 completing subject . All study medication self-administered except day pharmacokinetic sampling . All subject participate three sample period study day clinic admit overnight hospital .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Male nonpregnant , nonnursing female age &gt; 18 year good health Provision inform consent study . HIVuninfected . A prior negative HIV test ( ELISA ) must obtain enrollment . Willingness PK sample day clinic admit overnight hospital three occasion . Women childbearing potential must agree practice adequate method birth control study 30 day last dose study medication . Barrier method contraception abstinence sexual activity satisfactory method birth control . Karnofsky score â‰¥ 90 . Laboratory screen enrollment : Hematocrit &gt; 30 percent ( recent value ) AST &lt; 2 time upper limit normal ALT &lt; 2 time upper limit normal Bilirubin &lt; 2 time upper limit normal Creatinine &lt; 1.5 time upper limit normal Negative urine drug screen Pregnancy breastfeeding . Use medication food potential alter concentration raltegravir rifapentine , within 14 day prior period pharmacokinetic monitoring . Known intolerance raltegravir rifamycin antibiotic prior use last 30 day . Weight le 46 kg great 102 kg . Prior gastrointestinal surgery . Infection Hepatitis B Hepatitis C serology . Comorbidity concomitant , current medication take regularly . If concomitant medication take intermittently , medication potential alter concentration raltegravir rifapentine . Current imprisonment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Rifapentine</keyword>
	<keyword>Drug Kinetics</keyword>
</DOC>